Wisconsin Legislature: Drugs

Brand name drug manufacturer discounts used to reduce cost sharing charged to enrollees [Sec. 2922, 2956, 9323 (2)] [original bill only] - AB68

Brand name drug manufacturer discounts used to reduce cost sharing charged to enrollees [Sec. 2922, 2956, 9323 (2)] - SB111

Clinician-administered drugs: certain practices prohibited re state’s insurance unfair marketing and trade practices law - AB718

Clinician-administered drugs: certain practices prohibited re state’s insurance unfair marketing and trade practices law - SB753

Copayment for prescription drugs under MA eliminated [Sec. 1017-1020] [original bill only] - AB68

Copayment for prescription drugs under MA eliminated [Sec. 1017-1020] - SB111

Cost sharing payments for prescription drugs under MA eliminated - AB559

Cost sharing payments for prescription drugs under MA eliminated - SB552

DHS to reimburse ambulance service providers for replacement sets of epinephrine auto-injectors or kits under certain conditions; pharmacist may substitute a drug product prescribed to counteract anaphylaxis under set conditions; UW System, TCS, and special education aid funding from certain federal aid - AB740

Drug and alcohol testing following officer-involved critical incidents: law enforcement agencies required to adopt written policy - AB334

Drug and alcohol testing following officer-involved critical incidents: law enforcement agencies required to adopt written policy - SB476

Drug Evaluation and Classification Program in DOT: funding provision - AB1141

Epinephrine prefilled syringes: authorities for prescription, possession, and administration of epinephrine auto-injectors expanded to include; statewide standing order provision - AB337

Epinephrine prefilled syringes: authorities for prescription, possession, and administration of epinephrine auto-injectors expanded to include; statewide standing order provision - SB343

Federal drug pricing program (340B program) participants: reimbursing certain entities and imposing a fee or other adjustment prohibited - AB550

Federal drug pricing program (340B program) participants: reimbursing certain entities and imposing a fee or other adjustment prohibited [Sec. 2969] [original bill only] - AB68

Federal drug pricing program (340B program) participants: reimbursing certain entities and imposing a fee or other adjustment prohibited [Sec. 2969] - SB111

Federal drug pricing program (340B program) participants: reimbursing certain entities and imposing a fee or other adjustment prohibited - SB542

Hospitals participating in federal drug pricing program (340B program): prescription drug cost reporting [Sec. 2966] [original bill only] - AB68

Hospitals participating in federal drug pricing program (340B program): prescription drug cost reporting [Sec. 2966] - SB111

Insulin: cost sharing under health insurance policies and plans capped - AB552

Insulin: cost sharing under health insurance policies and plans capped - SB546

Insulin cost-sharing cap imposed [Sec. 2923, 2972-2974, 9423 (2)] [original bill only] - AB68

Insulin cost-sharing cap imposed [Sec. 2923, 2972-2974, 9423 (2)] - SB111

Insulin safety net programs created - AB557

Insulin safety net programs created [Sec. 2968] [original bill only] - AB68

Insulin safety net programs created [Sec. 2968] - SB111

Insulin safety net programs created - SB553

Kratom products made from the leaf of the Mitragyna speciosa plant: manufacture, distribution, delivery, and possession regulated - AB599

Kratom products made from the leaf of the Mitragyna speciosa plant: manufacture, distribution, delivery, and possession regulated - SB958

Medical aid in dying provisions created; JRCCP may report - AB1078

Medical aid in dying provisions created; JRCCP may report - SB1013

Medical marijuana program created, license provisions; Medical Marijuana Regulatory Commission created and attached to DOR; excise tax, criminal provisions, Prescription Drug Monitoring Program, fair employment law, UI, and WC provisions; JRCCP may report - AB1067

Medication-assisted treatment for substance use grants expansion - AB845

Medication-assisted treatment for substance use grants expansion - SB1033

Medication-assisted treatment grants re opioid dependence [Sec. 782] [original bill only] - AB68

Medication-assisted treatment grants re opioid dependence [Sec. 782] - SB111

Multidistrict opiate litigation settlement: AG to cooperate with local governments; conditions specified - AB374

Multidistrict opiate litigation settlement: AG to cooperate with local governments; conditions specified - SB386

Off-label therapies: access to by terminally ill patients - AB979

Opioid and methamphetamine data system: DOA to administer contract with vendor and collaborate with other departments; report required [Sec. 2288, 9101 (3)] [original bill only] - AB68

Opioid and methamphetamine data system: DOA to administer contract with vendor and collaborate with other departments; report required [Sec. 2288, 9101 (3)] - SB111

Opioid and methamphetamine data system: DOA to establish, collect data from other departments, and submit report to JCF - AB41

Opioid and methamphetamine data system: DOA to establish, collect data from other departments, and submit report to JCF [S.Amdt.2: appropriation removed] - SB49

Opioid and methamphetamine data system established; data collected from certain departments, report to JCF required - AB444

Opioid and methamphetamine data system established; data collected from certain departments, report to JCF required - SB439

Patient pharmacy benefit tool re cost of prescription drugs: grants to develop and implement [Sec. 2910] [original bill only] - AB68

Patient pharmacy benefit tool re cost of prescription drugs: grants to develop and implement [Sec. 2910] - SB111

Patient pharmacy benefit tool re cost of prescription drugs: grants to develop and implement; special education, UW System, and TCS funding provision - AB549

Patient pharmacy benefit tool re cost of prescription drugs: grants to develop and implement - SB554

Pharmacist training on dispensing opioid antagonists required [Sec. 2879, 2882, 9138 (2)] [original bill only] - AB68

Pharmacist training on dispensing opioid antagonists required [Sec. 2879, 2882, 9138 (2)] - SB111

Pharmacists authorized to extend a prescription order: 2019 WisAct 185 provisions extended - AB1

Pharmacists authorized to extend a prescription order: 2020 public health emergency provision extended - SB149

Pharmacists authorized to extend a prescription order, expires December 31, 2021 - AB31

Pharmacy benefit manager license and regulation requirements; pharmacy requirements re drug substitution, listing of retail prices and generic and corresponding brand name drugs, and notification of changes to prescription benefits [Sec. 730, 733, 734, 1117, 2163, 2397, 2885-2887, 2906, 2911, 2924, 2926, 2954, 2955, 2959-2963, 2965, 2987-3009, 9123 (1), 9323 (1), 9423 (1)] [original bill only] - AB68

Pharmacy benefit manager licensure requirements and regulations; cost-sharing limitation; specified disclosures to customers; notification of drug substitution - AB7

Pharmacy benefit manager licensure requirements and regulations; cost-sharing limitation; specified disclosures to customers; notification of drug substitution - SB3

Pharmacy technicians authorized to administer vaccines; any health care provider authorized to administer vaccines may supervise pharmacy students administering vaccines [A.Amdt.1: adds administration of specified drugs for adverse reactions; S.Amdt.1: adds use of the title “pharmacist” provision] - AB4

Prescription Drug Affordability, Office of, in the OCI: funding for establishment of and FTE positions - AB556

Prescription Drug Affordability, Office of, in the OCI: funding for establishment of and FTE positions - SB578

Prescription Drug Affordability Review Board created - AB544

Prescription Drug Affordability Review Board created [Sec. 67, 88, 2914-2917, 9123 (8), 9423 (4)] [original bill only] - AB68

Prescription Drug Affordability Review Board created [Sec. 67, 88, 2914-2917, 9123 (8), 9423 (4)] - SB111

Prescription Drug Affordability Review Board created - SB540

Prescription drug cost reporting by manufacturers: requirements established - AB512

Prescription drug cost reporting by manufacturers: requirements established - SB499

Prescription drug cost reporting requirements [Sec. 2953, 2967, 9123 (3)] [original bill only] - AB68

Prescription drug cost reporting requirements [Sec. 2953, 2967, 9123 (3)] - SB111

Prescription drug importation program established [Sec. 2912, 9123 (2)] [original bill only] - AB68

Prescription drug importation program established; JCF approval required - AB548

Prescription drug importation program established [Sec. 2912, 9123 (2)] - SB111

Prescription drug importation program established; JCF approval required - SB539

Prescription drug limits prohibition enacted in 2019 WisAct 185 reinstated - AB1

Prescription drug limits prohibition enacted in 2019 WisAct 185 reinstated, period specified - AB31

Prescription drug limits prohibition enacted in 2019 WisAct 185 reinstated, period specified - SB130

Prescription Drug Monitoring Program: certain exemption to review of patient’s records repealed - AB430

Prescription Drug Monitoring Program: certain exemption to review of patient’s records repealed - SB407

Prescription drug payments made by enrollee applied to health insurance out-of-pocket maximum or cost-sharing requirements - AB184

Prescription drug payments made by enrollee applied to health insurance out-of-pocket maximum or cost-sharing requirements - SB215

Reckless handling of a vaccine or drug rendering it ineffective or unusable made a felony; JRCCP may report - AB225

Reckless handling of a vaccine or drug rendering it ineffective or unusable made a felony; JRCCP may report [S.Amdt.1: "reckless handling" changed to "intentional destruction"] - SB242

State prescription drug purchasing entity study - AB558

State prescription drug purchasing entity study [Sec. 9123 (6)] - SB111

State prescription drug purchasing entity study [Sec. 9123 (6)] [original bill only] - AB68

State prescription drug purchasing entity study - SB551